Category
North America
Coverage of the United States and Canada: coverage determinations, drug pricing policy, regulatory decisions and the assessment bodies that inform them.
358 articles in this topic.
Articles in this category

11/18/2026
Ivonescimab Complete Response Letter: FDA Lists Four Reasons
The FDA complete response letter for ivonescimab (BLA 761524) cites China-heavy trial data, a modest PFS gain and the need for a new multiregional trial. Summit must resubmit or take another action within one year.
Read Article →
11/18/2026
FDA Launches Global Reliance Disclosure Program for Approval Packages
The FDA's Global Reliance Disclosure Program lets companies pass minimally redacted approval packages to regulators outside the US. Lenacapavir is the launch case, and the FDA intends to widen the program in January 2027. #SyenzaNews #MarketAccess
Read Article →
11/17/2026
FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap
FDA rejects ivonescimab lung cancer treatment: the trial slowed progression, but the overall survival benefit did not reach statistical significance.
Read Article →
11/16/2026
Learning Health System Frameworks and AI in US Care: A Scoping Review
A scoping review of 54 learning health system framework studies and 31 AI studies in US care finds that AI work mostly stops at turning data into knowledge. Only three AI studies reached practice, and none described feedback from deployment back into the model. #SyenzaNews #MarketAccess
Read Article →
11/13/2026
ACS Updates Prostate Cancer Screening Guideline for PSA Testing
"The American Cancer Society has updated its prostate cancer screening guideline, with regular PSA testing for average-risk men aged 50 to 69." #SyenzaNews #ProstateCancer
Read Article →
11/12/2026
Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa
Aspen Pharmacare has received approval for generic semaglutide in Brazil and South Africa, following Canada in July. Launches in all three markets are expected over the coming months. #SyenzaNews #MarketAccess
Read Article →
11/12/2026
US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%
A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.
Read Article →
11/10/2026
FDA Adds Warning on NAION Risk with GLP-1 Receptor Agonists
FDA is requiring every GLP-1 receptor agonist label to carry a warning on NAION, a rare eye condition that can cause permanent vision loss. #SyenzaNews #drugsafety #GLP1
Read Article →
11/10/2026
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo
The FDA approved Sunharbo (asundexian), the first factor XIa inhibitor for stroke prevention, for adults after a recent ischemic stroke or high-risk TIA. #SyenzaNews #MarketAccess
Read Article →
11/9/2026
CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs
CMS finalizes the GLOBE Model drug pricing rule, benchmarking Medicare Part B drug rebates against international prices from April 2027. #SyenzaNews #MarketAccess
Read Article →
11/9/2026
Medicare drug price negotiation: CMS sets permanent rules
The final rule also covers a temporary price floor for small biotech drugs and Part D plan payments to dispensing entities. #SyenzaNews #DrugPricing #MarketAccess
Read Article →
11/9/2026
Zepbound and Foundayo telehealth access via Hims & Hers
Eli Lilly and Hims & Hers Health agreed to widen Zepbound and Foundayo telehealth access, with self-pay prices starting at $149 per month. #SyenzaNews #obesity #telehealth
Read Article →


